Last reviewed · How we verify
[14C]-GSK3640254 intravenous infusion
[14C]-GSK3640254 intravenous infusion is a Small molecule drug developed by ViiV Healthcare. It is currently in Phase 1 development.
At a glance
| Generic name | [14C]-GSK3640254 intravenous infusion |
|---|---|
| Sponsor | ViiV Healthcare |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- [14C]-GSK3640254 intravenous infusion CI brief — competitive landscape report
- [14C]-GSK3640254 intravenous infusion updates RSS · CI watch RSS
- ViiV Healthcare portfolio CI
Frequently asked questions about [14C]-GSK3640254 intravenous infusion
What is [14C]-GSK3640254 intravenous infusion?
[14C]-GSK3640254 intravenous infusion is a Small molecule drug developed by ViiV Healthcare.
Who makes [14C]-GSK3640254 intravenous infusion?
[14C]-GSK3640254 intravenous infusion is developed by ViiV Healthcare (see full ViiV Healthcare pipeline at /company/viiv-healthcare).
What development phase is [14C]-GSK3640254 intravenous infusion in?
[14C]-GSK3640254 intravenous infusion is in Phase 1.